NBY  Novabay Pharmaceuticals Inc.




Consumer Durables


Major Pharmaceuticals

Market Cap.


Vuru Grade


Current Price

+0.0201 (+3.1905%)

Stability Price

Overvalued by 54.59%

Company Metrics

  • 0 P/E
  • 29.5665 P/S
  • 18.0000 P/B
  • -0.3210 EPS
  • -2,078.99% Cash ROIC
  • 1.62 Cash Ratio
  • 0 / N/A % Dividend
  • 448,608.00 Avg. Vol.
  • 39.78M Market Cap.

Company Description

NovaBay Pharmaceuticals Inc., a clinical stage biotechnology company, engages in developing proprietary and patented topical Aganocide compounds for the treatment and prevention of various infections without causing bacterial resistance. Its Aganocide compounds are synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white bloo...

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Maxim Weighs in on Biotech Stocks: StemCells Inc (STEM), NovaBay ...
Smarter Analyst - May 15, 2015
Jason Kolbert of Maxim Group rates stocks in the biotechnology sector and he's ranked #2811 out of 3602 analysts on TipRanks. Yesterday, Kolbert made two news ratings for StemCells Inc (NASDAQ:STEM) and NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals (NBY) Announces Quarterly Earnings Results - WKRB News
Maxim Rates NovaBay At Buy, Says 'The Eyes Have It!'
Benzinga - Apr 30, 2015
In a report published Thursday, analysts at Maxim Group initiated coverage of NovaBay Pharmaceuticals, Inc. (NYSE: NBY) with a Buy rating and a price target of $2.
NovaBay Pharmaceuticals Now Covered by Analysts at Maxim Group (NBY) - sleekmoney
Novabay Pharmaceuticals' CEO Dr. Ramin Najafi Interviewed by The Life ...
CNNMoney - Jun 25, 2015
What a difference just nine months can make. NovaBay Pharmaceuticals Inc. (NYSE MKT: NBY) has a materially derisked business strategy with new products coming rapidly to market, big-time distribution partners in place and new shareholders embracing ...
A Clear Vision for a Turnaround: Ron Najafi of NovaBay Pharmaceuticals - InvestorIdeas.com (press release)
NovaBay Pharmaceuticals, Inc. Price Target Update
OTC Outlook - Jun 9, 2015
NovaBay Pharmaceuticals, Inc. shares have received a Mean Price Target of $1.72. According to the rating issued from 3 Wall Street Analysts, the High Price Target is seen at $2 while the Lower end of the Price Target is seen at $1.25.
This Week's Morning Information: NovaBay Pharmaceuticals, Inc. (NBY ...
WallStreet Scope - 3 hours ago
NovaBay Pharmaceuticals, Inc. (NBY) performed sub average on Thursday with a 7 day performance of -7.46% finishing the day at $0.65, gaining 3.19%.
Short Interest in NovaBay Pharmaceuticals Expands By 15.6% (NBY)
Dakota Financial News - Jun 25, 2015
NovaBay Pharmaceuticals, Inc (NYSE:NBY) is a clinical-stage biotechnology company focused on addressing the unmet therapeutic needs of the global anti-infective market.
Trending Tickers: Zosano Pharma Corporation (NASDAQ:ZSAN), NovaBay ... - Stock Transcript
NovaBay Pharmaceuticals Appoints Mark M. Sieczkarek Chairman
Business Wire (press release) - Apr 14, 2015
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing topical non-antibiotic antimicrobial products for the global eye care market, announces the ...
New Laboratory Study Shows that NovaBay Pharmaceuticals' Avenova ...
Business Wire (press release) - May 6, 2015
BUSINESS WIRE)--Phoenix Eye Care and NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY) announced that Dr. Arthur B. Epstein, Director of Clinical Research and head of the Dry Eye - Ocular Surface Disease Center at Phoenix Eye Care, discussed the ...
NovaBay Pharma (NBY) Announces Presentation of Positive Avenova Reserach ... - StreetInsider.com
NovaBay Pharmaceuticals Receives Noncompliance Notice from NYSE MKT
Business Wire (press release) - May 1, 2015
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY) today announced receipt of a letter from NYSE MKT LLC (“NYSE MKT” or the “Exchange”) on April 28, 2015, stating that its stockholders equity, as of December 31, ...
Novabay Pharmaceuticals Receives New Coverage from Analysts at Maxim ... - Dakota Financial News
NovaBay Pharmaceuticals Reports 2015 First Quarter Financial Results and ...
Business Wire (press release) - May 14, 2015
BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing topical non-antibiotic antimicrobial products for the global eye care market, today reported financial results for the three ...